Novartis Xiidra Buy Looks Even Pricier With File Pulled In EU
EMA Questions Efficacy Of Eye Drop
A year after inking a multi-billion dollar deal to get hold of the Takeda eye drop, Novartis has given up on getting approval for Xiidra in Europe with the EMA unconvinced about the therapy's efficacy.
